Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $12.91

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $12.25.

CMPX has been the subject of a number of analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Citizens Jmp restated a “market outperform” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 28th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Wall Street Zen lowered Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently modified their holdings of CMPX. Suvretta Capital Management LLC grew its holdings in Compass Therapeutics by 0.6% during the fourth quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after purchasing an additional 81,220 shares during the period. Vivo Capital LLC raised its holdings in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after purchasing an additional 3,502,000 shares during the period. BVF Inc. IL raised its holdings in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after purchasing an additional 3,014,842 shares during the period. Vanguard Group Inc. boosted its position in shares of Compass Therapeutics by 45.6% during the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after purchasing an additional 2,212,794 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Compass Therapeutics by 57.4% during the fourth quarter. State Street Corp now owns 4,890,525 shares of the company’s stock worth $26,262,000 after purchasing an additional 1,784,012 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Up 4.1%

Compass Therapeutics stock opened at $2.27 on Friday. The business’s 50-day simple moving average is $2.21 and its 200 day simple moving average is $4.43. The stock has a market cap of $408.80 million, a price-to-earnings ratio of -5.54 and a beta of 0.90. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). As a group, sell-side analysts expect that Compass Therapeutics will post -0.42 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.